BLOG

Miltenyi Car T Cell Engineering for Immunotherapy Research – SelectScience

2017-07-04 Michael Zand NEWS

Editorial Article: T Cell Engineering for Breakthrough Immunotherapy Research – SelectScience

SelectScienceEditorial Article: T Cell Engineering for Breakthrough Immunotherapy ResearchSelectScienceImmunotherapy is one of the most exciting areas of cancer research today. Metastatic cancer, in particular, remains particularly challenging, as a sy… Continue reading

2017-07-04 Michael Zand NEWS

Editorial Article: T Cell Engineering for Breakthrough Immunotherapy Research – SelectScience

2017-07-04 Michael Zand NEWS

Stem cell therapy for chronic bladder ischaemia – Nature.com

Stem cell therapy for chronic bladder ischaemiaNature.comIn a rat model of atherosclerosis-induced chronic bladder ischaemia, bladder overactivity could be improved by human amniotic-fluid-derived stem cell (hAFSC) treatment. Following arterial balloon… Continue reading

2017-07-04 Michael Zand NEWS

Seed Company Secures CRISPR Rights – whotv.com

SelectScience

Miltenyi Car T Cell Engineering for Immunotherapy Research
SelectScience
Discover the world’s only fully automated, GMP-compliant, CAR T cell manufacturing system from Miltenyi Biotec.

and more »

2017-07-04 Michael Zand NEWS

Unlikely new problem emerges for immunotherapy trials – The Pharma Letter (registration)

The Pharma Letter (registration)Unlikely new problem emerges for immunotherapy trialsThe Pharma Letter (registration)Given the prevalence of cancer, not having enough patients to test the potential cancer treatments of tomorrow might seem an unlikely p… Continue reading

2017-07-04 Michael Zand NEWS

Defining the Future of the Stem Cell Industry – Interviews with Stem Cell Industry Executives – Research and Markets – Business Wire (press release)

TMR Research Blog (press release) (blog)Defining the Future of the Stem Cell Industry – Interviews with Stem Cell Industry Executives – Research and MarketsBusiness Wire (press release)Stem cell research has been in process for over five decades. Stem … Continue reading

2017-07-04 Michael Zand NEWS

Ryboquin raises £1.8m for drug development in gene therapy – Drug Target Review

whotv.com

Seed Company Secures CRISPR Rights
whotv.com
DuPont Pioneer Vice-President Neal Gutterson says, “We see CRISPR-Cas technology as an advancement in plant breeding which can enable a new era in crop improvement. This licensing agreement with ERS is a piece of DuPont Pioneer’s strategy to …

2017-07-04 Michael Zand NEWS

1
…
1,548
1,549
1,550
1,551
1,552
…
3,824

Drug Target Review

Ryboquin raises £1.8m for drug development in gene therapy
Drug Target Review
Ryboquin Limited announces that it has closed a £1.8m equity fund raising to accelerate product development in gene therapy.
Tycoons fund biotech firm with ambitions to ‘revolutionise’ cancer …Herald Scotland

all 3 news articles »

Login

Cart

Miltenyi Car T Cell Engineering for Immunotherapy Research – SelectScience

Editorial Article: T Cell Engineering for Breakthrough Immunotherapy Research – SelectScience

Editorial Article: T Cell Engineering for Breakthrough Immunotherapy Research – SelectScience

Stem cell therapy for chronic bladder ischaemia – Nature.com

Seed Company Secures CRISPR Rights – whotv.com

Unlikely new problem emerges for immunotherapy trials – The Pharma Letter (registration)

Defining the Future of the Stem Cell Industry – Interviews with Stem Cell Industry Executives – Research and Markets – Business Wire (press release)

Ryboquin raises £1.8m for drug development in gene therapy – Drug Target Review